Free Trial
NASDAQ:HLVX

HilleVax Q4 2024 Earnings Report

HilleVax logo
$1.88 +0.03 (+1.62%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.88 0.00 (0.00%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.33
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 28, 2025
Conference Call Time
5:00PM ET

Upcoming Earnings

HilleVax's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HilleVax Earnings Headlines

Brokerages Set HilleVax, Inc. (NASDAQ:HLVX) PT at $3.00
"I'm risking my reputation on this"
Crypto book predicted the last bull run (get it FREE now) This newly updated edition contains everything we've learned from interviewing the biggest names in crypto on our Crypto 101 podcast, which has over 17 million downloads and 600+ episodes. "Crypto Revolution" isn't just another book – it's your roadmap to potentially life-changing wealth in the current crypto bull run
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat